Quick Answer
Keros Therapeutics, Inc. reported Net Income Loss of $87.01 million for the year ending 2025.
- Keros Therapeutics, Inc. showed an increase of +146.4% in Net Income Loss from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Net Income Loss has grown by 805.4%.
- Historical annual values: Fiscal year 2025: $87.01 million | Fiscal year 2024: -$187.35 million | Fiscal year 2023: -$152.99 million | Fiscal year 2022: -$104.68 million | Fiscal year 2021: -$58.74 million | Fiscal year 2020: -$45.36 million | Fiscal year 2019: -$12.34 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: